- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Genentech changes distribution channels for bevacizumab
San Francisco, CA-After meeting with eye specialists Monday, Genentech Inc. will consider reversing a decision to narrow the supply channels for its drug bevacizumab (Avastin).
San Francisco, CA-After meeting with eye specialists Monday, Genentech Inc. will consider reversing a decision to narrow the supply channels for its drug bevacizumab (Avastin).
First the Southern San Francisco-based biotech company needs FDA clearance to continue allowing wholesalers to sell the drug to compounding pharmacies.
The company is forbidden by the FDA to use bevacizumab for any unapproved purposes.
Currently Genentech has postponed the restriction on bevacizumab sales until January 2008 so physicians can find other ways to obtain the product. Discussion also will be continued with the American Academy of Ophthalmology (AAO) and the American Society of Retina Specialists.
